Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID

• Status: Recruiting
• Trial end date: 2023-03-31
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Megan Nicklay
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• Prior confirmed COVID-19 diagnosis by standard RT-PCR assay or equivalent testing

• Persistent symptoms that continue four or more weeks after the start of a COVID-19 infection

• Quantified autonomic symptoms from at least one domain as reported by the patient on the screener Composite Autonomic Symptom Score (COMPASS-31). The COMPASS-31 assesses 6 domains of autonomic symptoms: Orthostatic Intolerance, Vasomotor, Secretomotor, Gastrointestinal, Bladder, and Pupillomotor.

• Quantified pain symptoms of pain interference or pain intensity as reported by the patient on the screener Patient-Reported Outcomes Measurement Information System (PROMIS-29)

Exclusion Criteria:

• Under age 18

• Prior SGB

• Allergy to amide local anesthetics (e.g., ropivacaine, bupivacaine/Marcaine)

• Pregnancy

• Current anticoagulant use

• History of a bleeding disorder

• History of glaucoma

• Infection or mass at injection site

• For the consistency of this study, patients who deny all autonomic symptoms on the COMPASS-31 or pain symptoms on the PROMIS-29 will also be excluded